Dry Eye Disease Clinical Trial
Official title:
Assessing a Self-care Management Program for Dry Eye Disease Patients Using the Health Educational Intervention Questionnaire
Dry Eye Disease (DED)is a chronic disease without a cure. Empowering patients to engage in better self-care requires knowledge of their disease and skills in self-management, which can lead to improved well-being and quality of life. The Investigation team has developed a DED self-management program (video series and educational booklet) that can be easily implemented into clinical use. The Investigators are going to use the Ocular Surface Disease Index (OSDI) to measure the dry eye in the participants. In addition, the research team plans to use the heiQ (validated questionnaire that assesses self-management and health education programs) to evaluate the DED self-management program by comparing results taken at baseline to 2 months after undergoing the self-management program.
The aim of this study is to assess a self-care management program for dry eye disease (DED)
patients using the Health Educational Intervention Questionnaire (heiQ). The heiQ is tool
that facilitates a comprehensive evaluation of patient education and self- management
interventions for patients with chronic conditions.
Dry Eye Disease is a chronic and may be a progressive condition. Currently, there is no gold
standard in the diagnosis or treatment of dry eye disease, but several management options are
available. Just like other chronic conditions like diabetes, patients with dry eye must
engage in disease modifying behaviours and perform self-care measures, in addition to taking
pharmaceutical agents. Patient education is the foundation of an effective management plan.
Various educational programs have been developed in the past for chronic diseases like
psoriasis, diabetes, and cardiovascular disease. However, there are limited studies
evaluating self-management and educational interventions for patients with ocular diseases or
DED. This research team has developed a program to educate patients on self-management of
DED. The educational component of the intervention includes a series of short videos and a
self-care handbook. Both the video series and handbook include topics ranging from the causes
of DED, basic anatomy of the eye, and self-care skills to manage DED symptoms in various
environments, such as the work environment and seasonal changes. This intervention aims to
deliver useful information about DED, increase patient knowledge and awareness of strategies
to reduce and manage symptoms of DED.
The research team will administer two questionnaires at two different time points to all
participants-once at baseline and once at two months post-intervention. The first
questionnaire is the Ocular Surface Disease Index (OSDI). This questionnaire is used to
determine the severity of dry eye symptoms. The second questionnaire is the Health
Educational Impact Questionnaire (heiQ). The heiQ is a validated instrument for health
education and self-management programs of chronic diseases. It is comprised of 40 questions
that represent 8 independent domains. Those domains include: Health-directed activity,
Positive and active engagement in life, Self-monitoring and insight, Constructive attitudes
and approaches, Skill and technique acquisition, Social integration and support, Health
service navigation, and Emotional distress. Results from the heiQ will serve to provide
evidence as to whether this educational intervention is effective and should be placed in
clinical practice.
Potential participants will be recruited through Dr. Mather's clinical practice at the Ivey
Eye Institute at St. Josephs's Hospital London, ON. A Letter of Information (LOI) and an
Invitation Poster will be mailed to potential participants. There will be approximately 130
participants recruited from Dr. Mather's Clinic at the Ivey Eye Institute. The participants
will be randomly assigned to the treatment arm or the controlled arm. The intervention in
total will take up to 4 hours (2 hours in both sessions). In the first session (baseline)
following the consent the first heiQ and OSDI will be completed by all the participants. The
treatment group (65 participants) will watch a series of educational videos and will leave
the baseline session with a DED handbook. The treatment group will agree not to share
information from the session and the DED handbook with anyone until after session two. During
the second session (2- months post intervention) all the participants will be asked to come
back to St. Joseph's hospital to complete the second heiQ and OSDI. At this session all
participants will be invited to watch the educational videos. All participants will be
provided a DED handbook and all the participants will be asked to complete a feedback survey
that will be provided. No data will be collected after the administration of the second set
of questionnaires. Participants that have questions if any will have the opportunity to ask
the ophthalmologist.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03216096 -
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT04656197 -
The Ocular Microbiome in Patients With Dry Eye Disease
|
||
Completed |
NCT05031806 -
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT03688802 -
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
|
Phase 2 | |
Completed |
NCT05213156 -
Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT04548427 -
Study to Evaluate the Efficacy and Safety of CKD-352
|
Phase 3 | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00395759 -
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
|
N/A | |
Completed |
NCT00680108 -
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
|
Phase 2 | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
Completed |
NCT01468168 -
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
|
Phase 2 | |
Completed |
NCT01014078 -
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT00799682 -
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
|
Phase 4 | |
Completed |
NCT05082974 -
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
|
Phase 3 | |
Recruiting |
NCT06146881 -
Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
|
Phase 2 | |
Completed |
NCT03292809 -
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
|
Phase 2/Phase 3 |